Navigation Links
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2011 and Provides Update on Development Activities
Date:8/4/2011

mon share, compared to net income of $0.2 million, or $0.02 per diluted common share, in the second quarter of 2010. Net loss for the six months ended June 30, 2011 increased to $9.6 million, or $0.99 per diluted common share, compared to net loss of $2.9 million, or $0.45 per diluted common share, in the same period of 2010.
  • An income tax recovery of $3.0 million was recorded in the second quarter of 2010, in relation to the Collaboration Agreement with Teva.
  • We had $75.4 million in cash, cash equivalents and short-term investments as of June 30, 2011, compared to $85.1 million as of December 31, 2010. As at August 1, 2011, we had 9,725,489 shares outstanding.

  • Conference Call DetailsOncoGenex will host a conference call at 4:30 p.m. Eastern Time today, Thursday, August 4, 2011, to provide a business update and discuss the second quarter financial results. A live event will be available through the Events and Presentations Web page found in the Investor Relations section of the OncoGenex Web site at www.oncogenex.com . Alternatively, you may access the live conference call by dialing (877) 606-1416 (U.S. & Canada) or (707) 287-9313 (International). A webcast replay will be available approximately two hours after the call and will be archived on www.oncogenex.com for 90 days.

    About OncoGenex PharmaceuticalsOncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug c
    '/>"/>

    SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. OncoGenex Announces Data Highlighting OGX-427 at American Association of Cancer Research (AACR) 102nd Annual Meeting 2011
    2. OncoGenex Pharmaceuticals to Participate in Panel Discussion on Novel Cancer Treatments at RBC Capital Markets Healthcare Conference
    3. Isis Pharmaceuticals to Receive $10 Million From OncoGenex License of OGX-011 to Teva
    4. OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
    5. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results
    6. Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society
    7. Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2011 Financial Results Webcast and Conference Call
    8. Visionary Pharmaceuticals, Inc., Announces Initial Seed Round Investments and the Launch of TH17 Autoimmune Disease Research Activities
    9. Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest Ortho Dermatologics Division
    10. Gamma Pharmaceuticals, Inc. Holds Special Shareholders Meeting
    11. Sigma-Tau Pharmaceuticals, Inc. Announces Addition of VP of Finance
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/29/2015)... June 30, 2015 Mordor Intelligence presents ... Primary Packaging Material (Plastic, Glass, Paper, Metal) - ByType of ... Pouches, Syringes, Tubes, Vials, Sachets) - By Geographical Region ( ... Asia Pacific , Latin America ... Africa ) - discussing Industry Value Chain Analysis, ...
    (Date:6/29/2015)... June 29, 2015  New guidelines released today ... Association give hope for better outcomes to the ... acute ischemic stroke each year. Stryker,s Trevo ® ... used in the clinical trials that provided data ... guidelines strongly recommend endovascular therapy with stent retrievers ...
    (Date:6/29/2015)... Minn. , June 29, 2015 EnteroMedics ... of devices that use neuroblocking technology to treat obesity, ... it has commenced an underwritten public offering of units. ... stock, Series A warrants to purchase common stock and ... purchase of units in the offering would result in ...
    Breaking Medicine Technology:Global Pharmaceutical Packaging Market - North America and Europe Expected to Lead Followed by the Asia Pacific Market 2Global Pharmaceutical Packaging Market - North America and Europe Expected to Lead Followed by the Asia Pacific Market 3New AHA Guidelines For The Early Management And Treatment Of Stroke Will Change The Standard Of Care For Thousands Of Stroke Patients Each Year 2New AHA Guidelines For The Early Management And Treatment Of Stroke Will Change The Standard Of Care For Thousands Of Stroke Patients Each Year 3EnteroMedics Inc. Announces Proposed Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Proposed Public Offering of Common Stock and Warrants 3
    ... June 21, 2011 Enox Biopharma, Inc. CEO, John C. ... Innovation Conference on Wednesday, June 22 at 12:15 AM EST. ... in Boston. The IN3 East meeting, hosted ... The meeting is designed to provide exposure and constructive interaction ...
    ... MOUNT LAUREL, N.J., June 21, 2011 ImpactRx, ... on physician prescribing behavior announced that Kjell Nygren, ... Analytical Services.  Kjell will strengthen the company,s position ... address clients, needs for better understanding the effectiveness ...
    Cached Medicine Technology:Enox Biopharma, Inc. Will Present at IN3 East Investment in Innovation Conference 2ImpactRx Names Kjell Nygren Vice President, Analytical Services 2
    (Date:6/30/2015)... , ... June 30, 2015 , ... Trenton Health Team ... the first Medicaid Accountable Care Organizations (ACO) in the State, serving the greater Trenton ... , The Trenton Health Team ACO draws on the collaborative structure of THT, bringing ...
    (Date:6/30/2015)... New Port Richey, FL (PRWEB) , ... June 30, 2015 , ... ... heroin use nearly doubled from 2007 to 2013 while heroin-related deaths more than tripled ... their greatest drug threat (1). Novus Medical Detox Center , a leading Florida-based ...
    (Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... Broadway by ... which features multiple patient and family member testimonials. Medicare rated the care center as ... plans to use the video to give future patients a firsthand look at the ...
    (Date:6/30/2015)... Scotch Plains, NJ (PRWEB) , ... June 30, 2015 , ... ... Dental Techniques, they will be wowed with the incredible care that they receive and ... quality care for their patients; but now they are proud to offer the same ...
    (Date:6/30/2015)... ... June 30, 2015 , ... ... general manager of HRA Healthcare Research & Analytics , a consultative healthcare ... Associates, Inc. (MJH) family of businesses. HRA offers quantitative and qualitative, custom and ...
    Breaking Medicine News(10 mins):Health News:Trenton Health Team Certified as Medicaid Accountable Care Organization 2Health News:Trenton Health Team Certified as Medicaid Accountable Care Organization 3Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 2Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 3Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 4Health News:Broadway by the Sea Video Promotes Top Quality Service 2Health News:NJ Top Dentist, Dr. Laurence C. Breiterman is Now Offering the WOW Factor at His Highly Regarded Dental Practice 2Health News:NJ Top Dentist, Dr. Laurence C. Breiterman is Now Offering the WOW Factor at His Highly Regarded Dental Practice 3Health News:NJ Top Dentist, Dr. Laurence C. Breiterman is Now Offering the WOW Factor at His Highly Regarded Dental Practice 4Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 2Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 3
    ... NHS treatments has been accused of placing money before ... anti-cancer drug. <BR.,Patients suffering from cancer linked to asbestos ... name is pemetrexed disodium, after a study ... (NICE). ,The group analyzed the cost effectiveness of ...
    ... a report of the Washington Post, the department of health of ... subject every district resident, between 14years and 84years, ... antibodies. , The launching of the campaign, to be ... with the 12th annual National HIV Testing Day. ,Gregg ...
    ... last year, surgeons from Australia had performed the first ever-triple ... Hospital had carried out the surgery on a 33-year-old woman, ... Myles was reported to be on her deathbed due to ... ,She was diagnosed when she was 19, with a rare ...
    ... lacking a gene for normal immune functioning found to ... //liver and spleen - a new study finds. ... pathogen called Leishmania donovani, affects certain internal organs. People ... often affected by this infectious disease through the bite ...
    ... department today advised people to take precautionary measures in view ... and jaundice during summer. // ,The people have ... minutes and wash raw vegetables and fruit thoroughly before eating, ... has also advised people to wash hands with soap after ...
    ... Lek has said that the country could be restricting a ... This is being done for the fear that most potential ... infertile couples seeking medical treatment to have babies, but they ... that such procedures would only be allowed if 'a particular ...
    Cached Medicine News:Health News:Lack of STAT1 -an Immune Protein, Pack Liver Infection Cure 2Health News:Lack of STAT1 -an Immune Protein, Pack Liver Infection Cure 3
    The URCA (Uric acid) method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of uric acid in serum, plasma and urine....
    For the quantitative in vitro determination of apolipoprotein A-1 (apo A-1) in serum and plasma. For use as an aid if assessing the risk of coronary artery disease....
    The GGT method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of g-glutamyl transferase activity in serum and plasma...
    For the quantitative in vitro determination of Triglycerides in serum and plasma....
    Medicine Products: